Takashima S, Kosaka T, Ueno K, Fujita H, Miyazaki I
Gan To Kagaku Ryoho. 1984 Nov;11(11):2362-71.
A prospective randomized study was performed for 72 patients with large bowel cancer, and 36 cases each of rectal cancer and colonic cancer, who had received curative resection respectively. The regimen consisted of two adjuvant chemotherapies: group A, postoperative administration of FT-207 suppository; group B; preoperative and postoperative administration of the same suppository. A follow-up study was then done. The results revealed the 5-year survival rate to be 65.1% for group A and 72.4% for group, B respectively. With rectal cancer, 5-year survival was 57.8% for group A and 70.5% for group B respectively. In colonic cancer the figures were 70.8% for group A and 75.0% for group B. Thus, there was no significant difference but a somewhat higher survival rate was observed in the preoperative plus postoperative administration group. Comparison of in the prognosis two groups classified according to the degree of nodal metastasis and invasion revealed good results in group B. The above-mentioned facts suggest that pre- and post-operative administration of FT-207 suppositories as adjuvant chemotherapy for colorectal cancer is superior to postoperative use alone.
对72例大肠癌患者进行了一项前瞻性随机研究,其中直肠癌和结肠癌各36例,均分别接受了根治性切除术。治疗方案包括两种辅助化疗:A组,术后给予FT - 207栓剂;B组,术前和术后均给予相同的栓剂。然后进行了随访研究。结果显示,A组的5年生存率分别为65.1%,B组为72.4%。对于直肠癌,A组的5年生存率分别为57.8%,B组为70.5%。在结肠癌中,A组的数字为70.8%,B组为75.0%。因此,两组之间没有显著差异,但术前加术后给药组的生存率略高。根据淋巴结转移程度和浸润情况对两组预后进行比较,结果显示B组效果良好。上述事实表明,FT - 207栓剂术前和术后给药作为大肠癌的辅助化疗优于单纯术后使用。